This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including disappointing cancer drug results, a hot new way to fight high cholesterol, and potential problems out of Europe for medical device companies.
In this video, health-care analyst David Williamson discusses today's mixed bag of results for Eli Lilly (NYSE:LLY) investors. Shares of the big pharma traded down after ramucirumab met its primary endpoints in a phase 3 trial for stomach cancer, but not in breast cancer.
Watch Market Checkup and find out why the surprise failure in treating breast cancer was so important, why the gastric cancer results may not be as good as the headlines, and what Eli Lilly's next moves are for this critical late-stage asset.
Follow David on Twitter: @MotleyDavid.
David Williamson owns shares of Eli Lilly. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Will 2018 Be Calumet Specialty Products Partners LP's Best Year Yet?
Rising sales volumes of specialty products hint at a great 2018 campaign.
This Is the Most Important Thing When It Comes to Paying Off Debt
Fixing finances is a popular New Year's resolution and there are ways to make it happen.
3 Smart Dividend ETFs for 2018
Don't miss out on these income-producing funds.